Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis [0.03%]
PARP抑制剂治疗实体瘤的静脉血栓事件风险:系统评价和Meta分析
S C Yazgan,E Yekedüz,E Akkuş et al.
S C Yazgan et al.
Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) are linked to thrombotic events, but the thrombosis risk in various cancers is unclear. This study evaluates the incidence and risk of venous thromboembolic even...
Multimodal AI-based risk stratification for distant metastasis in nasopharyngeal carcinoma [0.03%]
基于多模态AI的鼻咽癌远处转移风险分层模型研究
J Zhou,M S Wibawa,R Wang et al.
J Zhou et al.
Background: The TNM (tumour-node-metastasis) staging system is the primary tool for treatment decisions in nasopharyngeal carcinoma (NPC). However, therapeutic outcomes vary considerably between patients, and guidelines f...
Letter to the editor: The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinoma [0.03%]
读者来信:HRAS突变型头颈部鳞状细胞癌的免疫图景
D Zhang,Y Liu,M Li et al.
D Zhang et al.
Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations [0.03%]
提高精准肿瘤学的精确性:ESCAT II-III改变早期识别和靶向治疗的作用分子肿瘤委员会
V Seguí,J A Carbonell-Asins,J Martín-Arana et al.
V Seguí et al.
Background: The wide use of high-throughput technologies has facilitated the rise of precision medicine. The European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT) guide...
Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21) [0.03%]
前瞻性MIRINAE试验中新辅助化疗后残留侵袭性三阴性乳腺癌的基因组和转录组分析(KCSG-BR18-21,比较阿特珠单抗联合卡培他滨与单纯卡培他滨序贯辅助治疗的II期随机试验)
S-A Im,K Park,J Koh et al.
S-A Im et al.
Background: Profiling residual disease after neoadjuvant chemotherapy (NAC) might identify molecular target and tumor microenvironmental features to guide adjuvant therapy. We explored the characteristics of residual trip...
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer [0.03%]
年轻女性激素受体阳性、HER2阴性乳腺癌患者的基因组和临床特征
B Walbaum,O Martínez-Sáez,F Brasó-Maristany et al.
B Walbaum et al.
Background: Young women (≤40 years at diagnosis) with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) represent a high-risk group with distinct biologic...
Early detection, clinicopathological subtyping, and prognosis prediction for endometrial cancer patients using fragmentomics liquid biopsy assay [0.03%]
基于片断组学的液态活检技术在子宫内膜癌早期检测、临床病理分型及预后预测中的应用研究
Q Rao,H Zhou,W Weng et al.
Q Rao et al.
Background: Endometrial cancer (EC) is among the most prevalent gynecological malignancies worldwide. This study explores the use of cell-free DNA (cfDNA) fragmentomics to develop a non-invasive liquid biopsy assay, aimin...
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study [0.03%]
一种选择性RET抑制剂(BOS172738)治疗携带RET改变肿瘤(包括RET重排阳性非小细胞肺癌和RET突变型髓样甲状腺癌)患者的I期剂量递增/扩展多中心研究
P Schöffski,A Gazzah,J Trigo et al.
P Schöffski et al.
Background: This phase I dose-escalation (part A)/dose-expansion (part B) study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BOS172738 [a selective rearranged during transfection (...
Access to novel cancer medicines in Europe: inequities across countries and their drivers [0.03%]
欧洲各国新型癌症药物的可及性及其驱动因素所致的不平等现象
T Hofmarcher,A Charalambous,N Normanno et al.
T Hofmarcher et al.
Background: An increasing number of cancer medicines are being developed and approved. Access to these medicines is important for improving patient outcomes and overall quality of care, yet achieving equitable access acro...
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial) [0.03%]
头颈鳞状细胞癌伞式试验中的预测性生物标志物的鉴定(KCSG HN 15-16 TRIUMPH试验)
S Hwang,M H Hong,S H Shin et al.
S Hwang et al.
Background: Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is associated with a poor prognosis. Limited treatment options highlight the need for precision therapeutics. ...